NCT00004139View on ClinicalTrials.gov

Gemcitabine Plus Docetaxel or Irinotecan in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 30, 1999

Primary Completion Date

July 31, 2004

Study Completion Date

January 31, 2006

Conditions
Lung Cancer
Interventions
DRUG

docetaxel

DRUG

gemcitabine hydrochloride

DRUG

irinotecan hydrochloride

Trial Locations (8)

20007

Vincent T. Lombardi Cancer Research Center, Georgetown University, Washington D.C.

27710

Duke Comprehensive Cancer Center, Durham

29615

CCOP - Greenville, Greenville

38163

University of Tennessee, Memphis Cancer Center, Memphis

63110

Barnes-Jewish Hospital, St Louis

89106

CCOP - Southern Nevada Cancer Research Foundation, Las Vegas

20307-5000

Walter Reed Army Medical Center, Washington D.C.

29425-0721

Medical University of South Carolina, Charleston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Alliance for Clinical Trials in Oncology

OTHER

NCT00004139 - Gemcitabine Plus Docetaxel or Irinotecan in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter